EA201691046A1 - Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) - Google Patents

Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)

Info

Publication number
EA201691046A1
EA201691046A1 EA201691046A EA201691046A EA201691046A1 EA 201691046 A1 EA201691046 A1 EA 201691046A1 EA 201691046 A EA201691046 A EA 201691046A EA 201691046 A EA201691046 A EA 201691046A EA 201691046 A1 EA201691046 A1 EA 201691046A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrogen
lower alkyl
ethylimidazoline
mglur4
dion
Prior art date
Application number
EA201691046A
Other languages
English (en)
Other versions
EA029967B1 (ru
Inventor
Барбара Биманс
Вольфганг Губа
Георг Ешке
Антонио Риччи
Даниэль Рюхер
Эрик Виейра
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201691046A1 publication Critical patent/EA201691046A1/ru
Publication of EA029967B1 publication Critical patent/EA029967B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00Racemisation; Complete or partial inversion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы Iгде Y представляет собой C-R; Rявляется водородом или галогеном; Rявляется водородом или галогеном; Rявляется водородом, низшим алкилом или фенилом; Rявляется водородом или низшим алкилом; или Rи Rмогут образовывать вместе с соответствующими атомами, к которым они присоединены, следующие кольцаRявляется водородом или низшим алкилом; и если Rи Rобразуют кольцо, такое как описано выше, то Rявляется водородом; или Rи Rвместе с атомом углерода, к которому они присоединены, могут образовывать гетероциклоалкильное кольцо; Rявляется фенилом или пиридинилом, где атом N пиридинильной группы может находиться в разных положениях; или к их фармацевтически приемлемой соли или соли присоединения кислоты, к рацемической смеси или ее соответствующему энантиомеру, и/или оптическому изомеру, и/или стереоизомеру. Соединения могут применяться для лечения болезни Паркинсона, тревожного расстройства, тошноты и рвоты, обессивно-компульсивного расстройства, аутизма, при нейропротекции, лечении онкологического заболевания, депрессивного синдрома и диабета 2 типа.
EA201691046A 2014-01-10 2015-01-07 Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) EA029967B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14150700 2014-01-10
PCT/EP2015/050127 WO2015104271A1 (en) 2014-01-10 2015-01-07 Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators

Publications (2)

Publication Number Publication Date
EA201691046A1 true EA201691046A1 (ru) 2016-12-30
EA029967B1 EA029967B1 (ru) 2018-06-29

Family

ID=49917002

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691046A EA029967B1 (ru) 2014-01-10 2015-01-07 Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)

Country Status (22)

Country Link
US (1) US9695128B2 (ru)
EP (1) EP3092219B1 (ru)
JP (1) JP6263633B2 (ru)
KR (1) KR101868248B1 (ru)
CN (1) CN106170479B (ru)
AR (1) AR099047A1 (ru)
AU (1) AU2015205661B2 (ru)
BR (1) BR112016010168A2 (ru)
CA (1) CA2934768A1 (ru)
CL (1) CL2016001739A1 (ru)
CR (1) CR20160198A (ru)
EA (1) EA029967B1 (ru)
HK (1) HK1226054A1 (ru)
IL (1) IL245327B (ru)
MX (1) MX369820B (ru)
PE (1) PE20160860A1 (ru)
PH (1) PH12016501100A1 (ru)
SG (1) SG11201605557TA (ru)
TW (1) TWI649310B (ru)
UA (1) UA119053C2 (ru)
WO (1) WO2015104271A1 (ru)
ZA (1) ZA201602890B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3110802T1 (sl) * 2014-02-25 2019-01-31 F. Hoffmann-La Roche Ag Derivati etinila
RS58929B1 (sr) 2015-07-15 2019-08-30 Hoffmann La Roche Derivati etinila kao modulatori metabotropnih glutamatnih receptora
AR105556A1 (es) * 2015-08-03 2017-10-18 Hoffmann La Roche Derivados de etinilo
RU2745068C2 (ru) 2016-07-18 2021-03-18 Ф. Хоффманн-Ля Рош Аг Производные этинила
JP7364553B2 (ja) * 2017-08-17 2023-10-18 エフ. ホフマン-ラ ロシュ アーゲー パーキンソン病等の疾患を処置するためのイミダゾ[1,2-a]イミダゾール-2-オン誘導体
US10893929B2 (en) 2018-01-10 2021-01-19 Cook Medical Technologies Llc Vascular graft with compartments for compliance matching
US10517713B2 (en) 2018-01-10 2019-12-31 Cook Medical Technologies Llc Vascular graft with helical flow compliance compartments
AU2019309448A1 (en) 2018-07-26 2021-01-14 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013169A (es) * 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
CN102740699A (zh) * 2009-09-04 2012-10-17 范德比尔特大学 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US10533000B2 (en) * 2011-05-26 2020-01-14 Sunovion Pharmaceuticals, Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof

Also Published As

Publication number Publication date
PE20160860A1 (es) 2016-09-03
AR099047A1 (es) 2016-06-22
ZA201602890B (en) 2017-07-26
US20170008854A1 (en) 2017-01-12
SG11201605557TA (en) 2016-08-30
PH12016501100B1 (en) 2016-07-11
CL2016001739A1 (es) 2017-05-12
TWI649310B (zh) 2019-02-01
MX2016008887A (es) 2016-10-04
MX369820B (es) 2019-11-22
EP3092219B1 (en) 2018-09-19
AU2015205661B2 (en) 2018-08-23
UA119053C2 (uk) 2019-04-25
CR20160198A (es) 2016-06-17
HK1226054A1 (zh) 2017-09-22
KR101868248B1 (ko) 2018-06-15
IL245327A0 (en) 2016-06-30
CA2934768A1 (en) 2015-07-16
US9695128B2 (en) 2017-07-04
JP2017502066A (ja) 2017-01-19
IL245327B (en) 2018-12-31
KR20160095099A (ko) 2016-08-10
TW201531464A (zh) 2015-08-16
BR112016010168A2 (pt) 2017-08-08
CN106170479B (zh) 2019-02-12
EA029967B1 (ru) 2018-06-29
JP6263633B2 (ja) 2018-01-17
PH12016501100A1 (en) 2016-07-11
CN106170479A (zh) 2016-11-30
EP3092219A1 (en) 2016-11-16
WO2015104271A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MY183953A (en) Ethynyl derivatives
MX2016008536A (es) Derivados de fluoro-naftilo.
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
AR104863A1 (es) Derivados imidazol
EA201391538A1 (ru) Производные пиразолидин-3-она
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
PH12019500119A1 (en) Ethynyl derivatives
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
CY1118595T1 (el) Αρυλοαιθινυλο πυριμιδινες
EA201892640A1 (ru) Лечение болезни паркинсона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM